Skip to Content
Merck
All Photos(1)

Documents

AFRC 17D1

94120825, Application: Fusion partner for hybridoma production

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41106514

biological source

Horse x Mouse/Horse Hybridoma

ImmunoDon

Horse peripheral lymphocytes

Myeloma

NS0

Reactivity

Application: Fusion partner for hybridoma production

technique(s)

cell culture | mammalian: suitable

isotype

Not specified

shipped in

dry ice

storage temp.

−196°C

Cell Line Origin

Horse peripheral blood lymphocytes x Mouse NS0

Cell Line Description

The heterohybridoma AFRC 17D1 was obtained by fusion of lymphocytes from ponies immunised with the influenza A equine 2 virus (isolateA/Equine/Newmarket/79 (H3N8)) with mouse myeloma NS0 cells. The hybridoma was made aminopterin-sensitive by selective growth in 8-azaguanine. This non-Ig-secreting cell line was used as fusion partner for the establishment of equine-mouse heterohybidomas.

Immunogen

Influenza A equine 2 virus

Application

Fusion partner for hybridoma production

Culture Medium

RPMI 1640 + 2mM glutamine + 1mM Sodium Pyruvate (NaP) + 5% Foetal Bovine Serum (FBS)

Subculture Routine

Maintain cultures between 3-9x100,000 cells/ml; 5% CO2; 37°C

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Hybridoma Fusion Partners Cell Lines

Selection of the right fusion partner cell line is critical to obtain desired attributes of the hybridoma. Explore hybridoma fusion partners cell lines.

Related Content

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service